Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma

References

• ChuaMLKWeeJTSHuiEPChanATCNasopharyngeal carcinomaLancet2016387100221012102426321262
   PubMed Web of Science ®Google Scholar
• NgWTLeeMCHungWMClinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinomaInt J Radiat Oncol Biol Phys201179242042820452132
   PubMed Web of Science ®Google Scholar
• SunXSuSChenCLong-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicitiesRadiother Oncol2014110339840324231245
   PubMed Web of Science ®Google Scholar
• OuXZhouXShiQTreatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boostOncotarget2015635383813839726485757
   PubMedGoogle Scholar
• OoftMLBrauniusWWHeusPPrognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysisBiomark Med2015910997101026441207
   PubMed Web of Science ®Google Scholar
• ZhangPWuSKWangYp53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: a retrospective studyOncol Lett20159111311825435943
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalLancet Oncol2010111212819897418
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med2006354656757816467544
   PubMed Web of Science ®Google Scholar
• XiaWXLiangHLvXCombining cetuximab with chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a propensity score analysisOral Oncol20176716717428351572
   PubMedGoogle Scholar
• WuXHuangJLiuLCetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: a retrospective matched case-control studyMedicine (Baltimore)20169539e492627684830
   PubMedGoogle Scholar
• NiuXHuCKongLExperience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinomaJ Cancer Res Clin Oncol201313961063107123525586
   PubMed Web of Science ®Google Scholar
• MaBBKamMKLeungSFA phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinomaAnn Oncol20122351287129221948811
   PubMed Web of Science ®Google Scholar
• CrombetTOsorioMCruzTUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol20042291646165415117987
   PubMed Web of Science ®Google Scholar
• HuangJFZhangFZZouQZInduction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trialOncotarget2017822457246527974693
   PubMedGoogle Scholar
• WestphalMHeeseOSteinbachJPA randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastomaEur J Cancer201551452253225616647
   PubMed Web of Science ®Google Scholar
• ReddyBKLokeshVVidyasagarMSNimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patientsOral Oncol201450549850524613543
   PubMed Web of Science ®Google Scholar
• HuangXDYiJLGaoLMulti-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinomaZhonghua Zhong Liu Za Zhi200729319720117649636
   PubMedGoogle Scholar
• ZhaiRPYingHMKongFFExperience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinomaOnco Targets Ther201583383339026604795
   PubMed Web of Science ®Google Scholar
• YouRSunRHuaYJCetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II–IVb nasopharyngeal carcinomaInt J Cancer201714161265127628577306
   PubMed Web of Science ®Google Scholar
• ChanATTeoPMNganRKConcurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trialJ Clin Oncol20022082038204411956263
   PubMed Web of Science ®Google Scholar
• LeeAWLauWHTungSYPreliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study GroupJ Clin Oncol200523286966697516192584
   PubMed Web of Science ®Google Scholar
• BlanchardPLeeAMarguetSChemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysisLancet Oncol201516664565525957714
   PubMed Web of Science ®Google Scholar
• WangCFuXCaiXHigh-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapyOnco Targets Ther2016911712226766917
   PubMed Web of Science ®Google Scholar
• HeXXuJGuoWJiangXWangXZongDCetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary resultsFuture Oncol20139101459146724106897
   PubMed Web of Science ®Google Scholar
• FengHXGuoSPLiGRToxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinomaMed Oncol201431917025119503
   PubMed Web of Science ®Google Scholar
• LiYChenQYTangLQConcurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control studyBMC Cancer201717156728836950
   PubMedGoogle Scholar
• RamakrishnanMSEswaraiahACrombetTNimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originMAbs200911414820046573
   PubMed Web of Science ®Google Scholar